BKM120 in Cancers With PIK3CA Activating Mutations
Ontology highlight
ABSTRACT: In people whos cancers have a PIK3CA mutation, this trial will be evaluating the drug BKM120 as a possible treatment. BKM120 works by blocking the phosphatidylinositol-3-kinase (PI3K)pathway, thereby inhibiting tumor growth and survival.
The purpose of this study is to learn if the study drug BKM120 can shrink or slow the growth of your tumor. The safety of BKM120 will also be studied. Your physical state, symptoms, change in the size of your tumor, and laboratory findings obtained while you are on study will help the research team decide if BKM120 is safe and effective in patients with advanced cancers.
DISEASE(S): Lung Cancer,Advanced Solid Tumors,Colorectal Cancer,Breast Cancer,Solid Tumors,Cholangiocarcinoma
PROVIDER: 2117958 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA